Drug Database
BR

BRAF V600 (THxID BRAF test)

✓ Approved

bioMérieux · BRAF · Companion diagnostic

What is BRAF V600?

BRAF V600 is a companion diagnostic developed by bioMérieux. It is approved for therapeutic indications via others.

Drug Profile

Brand NamesTHxID BRAF test
CompanybioMérieux
Drug ClassCompanion diagnostic
Molecular TargetBRAF
RouteOthers
StatusApproved
Sources: ClinicalTrials.gov, bioMérieux

Mechanism of Action

Molecular Targets

BRAF V600 acts on 1 molecular target:

BRAFB-Raf proto-oncogene, serine/threonine kinase (RAFB1, NS7)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

BRAF V600 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

Related Research Articles

PubMedFrontiers in public health2026-10-22

Otoacariasis in East China: a case series of three tick bites with diagnostic and management challenges.

Niu Yongzhi Y, Jiang Wenxiu W, Chen Kaixuan K, Che Fei F et al.

Tick bites in the external auditory canal are rare but can pose diagnostic and management challenges in primary care settings. This case series aims to highlight diagnostic challenges and public health implications of otoacariasis in East China. We retrospectively reviewed three cases of tick bites that initially posed diagnostic and management challenges at primary hospitals in Qingdao, Jinan, and Shanghai. Clinical data, including presentation, initial diagnostic assessment, treatment, and follow-up, were extracted from electronic medical records. Case 1: a 70-year-old female with an engorged tick abdomen mistaken for the tympanic membrane. Case 2: a 3-year-old girl with retained tick mouthparts after forceful removal. Case 3: a 5-year-old girl with a tick on the tympanic membrane misidentified as a common insect. Key diagnostic clues included tick morphology, dark red feces, and leg movement. Topical 2% lidocaine effectively immobilized ticks for atraumatic extraction. These cases highlight a diagnostic and management gap in primary care settings in East China, underscoring the need for enhanced physician education and public awareness as a key public health strategy to promote early recognition and improve patient outcomes in the region.

PMID 42903160
Read full article →
PubMedCancer science2026-10-22

Diagnostic Performance of cfDNA-Based Liquid Biopsy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Liu Jiwei J, Zhang Yangyu Y, Yang Shuo S, Wu Yanhua Y et al.

Conventional surveillance tools for hepatocellular carcinoma (HCC) have limited sensitivity. Circulating cell-free DNA (cfDNA)-based liquid biopsy is a promising minimally invasive approach; however, its overall diagnostic performance remains unclear. This meta-analysis aimed to comprehensively evaluate the diagnostic accuracy of cfDNA-based liquid biopsy in HCC. Following PRISMA-DTA guidelines, we searched PubMed, EMBASE, and Web of Science until July 2026. Diagnostic accuracy data were pooled using bivariate random-effects models. Methodological quality was assessed using QUADAS-2 and NOS. A total of 29 studies (4250 HCC patients, 7982 controls) were included. Pooled sensitivity and specificity of cfDNA-based testing were 0.82 (95% CI: 0.76-0.86) and 0.91 (95% CI: 0.88-0.93). The area under the summary receiver operating characteristic curve (AUC) was 0.93 (95% CI: 0.91-0.96). Subgroup analyses showed higher sensitivity in advanced HCC 0.91 (95% CI: 0.85-0.95) than early HCC 0.77 (95% CI: 0.71-0.83). Methylation profiling yielded relatively higher sensitivity 0.84 (95% CI: 0.77-0.89), whereas fragmentomics showed relatively favorable specificity 0.93 (95% CI: 0.88-0.96). Combining cfDNA-based testing with alpha-fetoprotein (AFP) significantly improved sensitivity compared with cfDNA alone (0.78 vs. 0.65). No significant publication bias was detected (p = 0.83). cfDNA-based liquid biopsy achieves high diagnostic accuracy for HCC. As exploratory observations, methylation-based assays with relatively higher sensitivity may have potential value for screening high-risk populations, while fragmentomics-based assays with relatively favorable specificity may aid differential diagnosis. Combining cfDNA-based liquid biopsy with AFP further improves diagnostic performance, supporting cfDNA as a promising noninvasive tool for HCC detection. Trial Registration: This systematic review was registered on PROSPERO: CRD420261293877 (https://www.crd.york.ac.uk/PROSPERO/).

PMID 42902833
Read full article →
PubMedMusculoskeletal care2026-10-22

Clinical Correlations Between Diagnostic Assessment Methods and Functional Outcomes in Musculoskeletal Rehabilitation: A Narrative Review.

Nahum Rosenberg R

Musculoskeletal disorders are major contributors to pain, disability, reduced participation, and health-care utilisation. Structural and digital diagnostic tools can characterise pathology, but their ability to explain functional limitations and rehabilitation prognosis is often incomplete. This narrative review aimed to synthesise representative evidence on the relationship between diagnostic and screening methods and functional outcomes in musculoskeletal rehabilitation, with emphasis on clinical interpretation and practical use in care pathways. Peer-reviewed literature, supplemented by manual screening of relevant reference lists, was reviewed to identify publications available through March 2026. The synthesis prioritised studies linking diagnostic findings to patient-reported outcome measures (PROMs), performance-based tests, or real-world activity metrics. Conventional imaging, including ultrasound, computed tomography, and MRI, may identify clinically relevant pathology but often shows only modest concordance with pain, disability, and performance-based function. PROMs and brief performance tests provide the most direct functional anchors, whereas interpretation using the minimal clinically important difference (MCID) or responder thresholds is needed to distinguish statistically detectable associations from clinically meaningful change. Biomarkers and AI-supported analytics remain promising but insufficiently validated for independent functional prognostication. Wearable sensors appear most clinically useful for longitudinal monitoring of real-world activity, and brief psychosocial screening helps explain the discordance between structural findings and perceived disability. Functional prognosis in musculoskeletal rehabilitation should not rely on diagnostic findings alone. A multidimensional, function-centred first-visit bundle combining focused examination, one region-specific PROM, one brief performance test, and brief psychosocial risk screening may improve triage, patient communication, rehabilitation planning, and follow-up. Diagnostic escalation should be selective and reserved for red flags, management-changing pathology, or failure to improve on repeated standardised functional reassessment.

PMID 42902851
Read full article →
PubMedJournal of intellectual disabilities : JOID2026-10-22

Why clinicians in acute hospitals may fail to engage in direct communication with people with intellectual disability.

Elbagoury Amany A, Zia Asif A, Sawhney Indermeet I

This case highlights the healthcare inequities faced by people with intellectual disability, including diagnostic overshadowing, communication barriers, and the need for personalised, meaningful adjustments in care. A woman in her fifties with mild intellectual disability, epilepsy, and diabetes insipidus experienced delayed diagnosis and treatment because healthcare providers assumed she could not tolerate magnetic resonance imaging; however, when the scan was eventually completed with supported communication, it revealed a serious brain tumour with metastases. The case shows that diagnostic overshadowing can arise not only from misattributing symptoms, but also from untested assumptions about a patient's ability to engage with diagnostic procedures. It also underscores the importance of involving patients and families directly in healthcare decisions to support autonomy and prevent avoidable harm. Addressing these systemic issues is essential to deliver equitable, patient-centred care in acute hospital settings.

PMID 42902893
Read full article →
PubMedDanish medical journal2026-10-22

Non-adherence to diagnostic colonoscopy after positive faecal screening test.

Nielsen Christian Flindt CF, Al-Noori Ali A, Nielsen Nanna Mundbjerg NM, Gaarden Morten M et al.

The Danish Colorectal Cancer Screening Programme has achieved a high adherence, in the 88-90% range, to diagnostic colonoscopy following a positive immunochemical faecal occult blood test (iFOBT). However, a small subgroup does not proceed to colonoscopy. This study investigated factors associated with non-adherence to diagnostic colonoscopy in the North Denmark Region (NDR). In 2020, 278 had a positive iFOBT in the NDR and did not undergo subsequent colonoscopy. We conducted a two-part study consisting of 1) a journal audit assessing comorbidity, inflammatory bowel disease (IBD), hospitalisations and colonoscopy history, and 2) a questionnaire exploring self-reported reasons for non-adherence. Among 256 eligible individuals, 169 (66%) completed the questionnaire. The journal audit revealed that 25% of non-adherent individuals had an ASA score ≥ 3, 65% had a Charlson Comorbidity Index score ≥ 2 and 10% had known IBD. Furthermore, 20% had undergone a colonoscopy within the preceding two years. Questionnaire responses identified recent colonoscopy (n = 29) and haemorrhoids (n = 30) as frequent reasons for non-adherence. Many respondents reported non-medical reasons, including perceiving themselves as healthy, lacking understanding of the programme or finding colonoscopy unpleasant. Non-adherence to diagnostic colonoscopy after positive iFOBT is often not medically justified. The findings indicate a need for improved patient education. Enhanced general practitioner involvement may help address logistical and informational barriers. None. Not relevant.

PMID 42902752
Read full article →
PubMedMalawi medical journal : the journal of Medical Association of Malawi2026-10-22

Diagnostic value of cervical vascular ultrasound combined with CT angiography in carotid artery plaque in patients with cerebral infarction.

Qian Jingjiao J, Shi Hanwen H, Ye Pingping P, Wang Danni D et al.

To clarify diagnostic value of cervical vascular ultrasound (CVUS) combined with CT angiography (CTA) in carotid artery plaque in patients with cerebral infarction. A total of 110 patients with cerebral infarction upon admission to our hospital from January 2021 to December 2023 received enrollment and performed CVUS and CTA examination. Digital subtraction angiography (DSA) received application as the gold standard to compare the diagnostic efficiency of different detection methods. DSA examination was performed on the bilateral carotid arteries (220 carotid arteries) of 110 patients, and 194 plaques were detected, including 73 soft plaques, 93 hard plaques and 28 mixed plaques. A total of 174 carotid artery stenosis cases were detected, including 73 mild stenosis cases, 42 moderate stenosis cases, 36 severe stenosis cases and 23 complete stenosis cases. The accuracy rate of CVUS combined with CTA in detecting carotid artery plaque was 93.81% (182/194), higher than that of CVUS (75.77%, 147/194) and CTA (76.80%, 149/194), with significance (P<0.05). The accuracy of CVUS combined with CTA in detecting carotid artery stenosis was 94.83% (165/174) higher than that of CVUS (78.74%, 137/174) and CTA (84.48%, 147/174), with significance (P<0.05). CVUS combined with CTA has a high diagnostic accuracy for carotid artery plaque lesions in patients with cerebral infarction, providing the basis for clinical diagnosis and follow-up treatment.

PMID 42903001
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about BRAF V600